These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36694455)

  • 1. WHO guidelines on biosimilars: Toward improved access to safe and effective products.
    Kang HN; Wadhwa M; Knezevic I; Ondari C; Simao M
    Ann N Y Acad Sci; 2023 Mar; 1521(1):96-103. PubMed ID: 36694455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019.
    Kang HN; Thorpe R; Knezevic I;
    Biologicals; 2020 May; 65():1-9. PubMed ID: 32224101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory challenges with biosimilars: an update from 20 countries.
    Kang HN; Thorpe R; Knezevic I; Casas Levano M; Chilufya MB; Chirachanakul P; Chua HM; Dalili D; Foo F; Gao K; Habahbeh S; Hamel H; Kim GH; Perez Rodriguez V; Putri DE; Rodgers J; Savkina M; Semeniuk O; Srivastava S; Tavares Neto J; Wadhwa M; Yamaguchi T
    Ann N Y Acad Sci; 2021 May; 1491(1):42-59. PubMed ID: 33222245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance.
    Rahalkar H; Sheppard A; Salek S
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):215-236. PubMed ID: 35078378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products.
    Knezevic I; Griffiths E
    Ann N Y Acad Sci; 2017 Nov; 1407(1):5-16. PubMed ID: 28905423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience.
    Kurki P; Kang HN; Ekman N; Knezevic I; Weise M; Wolff-Holz E
    BioDrugs; 2022 May; 36(3):359-371. PubMed ID: 35596890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory evaluation of biosimilars throughout their product life-cycle.
    Kang HN; Knezevic I
    Bull World Health Organ; 2018 Apr; 96(4):281-285. PubMed ID: 29695884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June - 2 July 2021.
    Wadhwa M; Kang HN; Thorpe R; Knezevic I; ; Aprea P; Bielsky MC; Ekman N; Heim HK; Joung J; Kurki P; Lacana E; Njue C; Nkansah E; Savkina M; Thorpe R; Yamaguchi T; Wadhwa M; Wang J; Weise M; Wolff-Holz E; ; ; ; ; ; ; ;
    Biologicals; 2022 Apr; 76():1-9. PubMed ID: 35466023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval of biosimilars: a review of unsuccessful regulatory filings.
    Rathore AS; Chhabra H; Bhargava A
    Expert Opin Biol Ther; 2021 Jan; 21(1):19-28. PubMed ID: 32634326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval.
    Strauss DG; Wang YM; Florian J; Zineh I
    Clin Pharmacol Ther; 2023 Jan; 113(1):55-61. PubMed ID: 36178447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
    J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regulatory landscape of biosimilars: Algeria's efforts and progress made from 2006 to 2021.
    Benahzil MA; Hadjaz IM; Mansouri K
    Ann Pharm Fr; 2022 Jul; 80(4):440-447. PubMed ID: 34767827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
    Aapro M; Krendyukov A; Schiestl M; Gascón P
    BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.